XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.25.1

Investments | 3 Months Ended
--- | ---
Mar. 31, 2025
Investments, Debt and Equity Securities [Abstract] |
Investments | 6. Investments The carrying values of the Company's investments, by category, were as follows (in millions):
Date |  | Equity Method (1) |  | Fair Value (2) |  | Measurement Alternative (3) |  | Total
March 31, 2025 |  | $ | 0.9 |  |  | $ | 2.3 |  |  | $ | 0.9 |  |  | $ | 4.1 |
December 31, 2024 |  | $ | 0.9 |  |  | $ | 1.8 |  |  | $ | 0.9 |  |  | $ | 3.6 |
(1) The Company's equity method investments were comprised of MediBeacon and Scaled Cell as of both March 31, 2025 and December 31, 2024. (2) The Company's fair value investments in common stock are comprised of marketable equity securities in two publicly traded companies that were purchased in October 2024 and March 2025. (3) The Company's measurement alternative method investment was comprised of Triple Ring as of both March 31, 2025 and December 31, 2024. The Company's share of net losses from its equity method investments was $5.9 million and $1.2 million for the three months ended March 31, 2025 and 2024, respectively. MediBeacon Pansend accounts for its preferred stock investment in MediBeacon under the equity method of accounting, inclusive of any fixed maturity securities (notes) issued by MediBeacon to Pansend. On January 17, 2025, MediBeacon received approval from the U.S. Food and Drug Administration ("FDA") for its Transdermal GFR Measurement System ("TGFR"). Pursuant to the terms of MediBeacon's convertible notes, upon the FDA approval, Pansend's convertible notes of $11.4 million and the related accrued interest of $1.5 million, together totaling $12.9 million, were converted into Series 3 Preferred Stock. In addition, pursuant to its amended commercial partnership with Huadong and, as a result of FDA approval, a $7.5 million milestone payment from Huadong Medicine Co. Ltd ("Huadong"), a publicly traded company on the Shenzhen Stock Exchange, to MediBeacon for MediBeacon preferred stock was received in the first quarter of 2025. As a result of these transactions, Pansend's ownership in MediBeacon decreased from 45.9% prior to the transactions to 44.7% subsequent to the transactions. On a fully diluted basis, Pansend's ownership in MediBeacon decreased from 40.1% to 39.7%. As a result of these transactions, Pansend recognized a step-up gain of $4.4 million in Other (expense) income, net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2025, which increased Pansend's carrying amount of its investment in MediBeacon. Concurrently, Pansend recognized equity method losses of $5.9 million, driven by the $4.4 million step-up gain and $1.5 million of interest from the conversion of the convertible notes, which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero. MediBeacon's total outstanding principal amount of notes due to Pansend was $0.5 million and $12.0 million, as of March 31, 2025, and December 31, 2024, respectively. Interest income earned by Pansend from the MediBeacon notes totaled $0.1 million and $0.3 million for the three months ended March 31, 2025 and 2024, respectively, and the related accrued interest receivable was $0.3 million and $1.7 million, as of March 31, 2025 and December 31, 2024, respectively. As of March 31, 2025, Pansend's carrying amount of its investment in MediBeacon remained at zero, inclusive of the $0.5 million in secured promissory notes which were offset against recognized equity method losses, and Pansend has cumulative unrecognized equity method losses relating to MediBeacon of $15.4 million. Marketable Securities In October 2024, the Company purchased common shares in the open market of a publicly traded company for approximately $2.0 million, which represents less than 1% of the total outstanding common stock of the issuer. In March 2025, the Company purchased common shares in the open market of another publicly traded company for $0.3 million, which represents less than 1% of the total outstanding equity of the issuer. These securities are remeasured at fair value each reporting period using the externally quoted market prices, Fair Value Level 1 inputs. For the three months ended March 31, 2025, unrealized fair value gains of $0.2 million related to these securities were included in Other income (expense), net in the Condensed Consolidated Financial Statements.

X
- Definition The entire disclosure for investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details
Name: | us-gaap_InvestmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration